

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

DAPOXETINE (e.g. PRILIGY®) FOR PREMATURE EJACULATION

BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR SECONDARY CARE

Mid and South Essex CCGs do not support the prescribing of dapoxetine (e.g. Priligy®) for the treatment of premature ejaculation.

Dapoxetine is a short-acting selective serotonin re-uptake inhibitor (SSRI) licensed for use in the treatment of premature ejaculation in men who meet all of the following criteria: poor control over ejaculation, a history of premature ejaculation over the past six months, marked distress or interpersonal difficulty as a consequence of premature ejaculation, and an intravaginal ejaculatory latency time of less than two minutes.

The East of England Priorities Advisory Committee has advised that commissioning of dapoxetine is low priority and is not recommended ([PAC guidance](#), March 2014).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	East of England Priorities Advisory Committee Guidance Statement: Dapoxetine (Priligy®) for premature ejaculation: https://www.prescgipp.info/media/3187/dapoxetine.pdf
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	May 2021; May 2021
Review Date	May 2026 or sooner if subject to any new updates nationally